Advanced Solid Tumor CancerPhase 1GH2616C102NCT07260513
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
A Phase 1 study testing GH2616 Tablets for oral administration at specified doses on scheduled days. in people with Advanced Solid Tumor Cancer, run by Suzhou Genhouse Bio Co., Ltd. at 2 sites in China.
Trial summary
GH2616 is a potent and selective inhibitor targeting KIF18A, exhibiting distinct and superior anticancer properties compared to other cell cycle and anti-mitotic drug targets, with significant inhibitory effects on TP53 mutant and WGD (whole genome doubling) or CIN (chromosomal instability) tumors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Solid Tumor Cancer
- What is being tested?
- GH2616 Tablets for oral administration at specified doses on scheduled days.
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 126 participants
- Where
- 2 sitesChina
- Study dates
- 27 Mar 2025to 31 Dec 2030
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1.Female, aged ≥18 years. 2.Assessed by the investigator as suitable for participation in this study in the following two aspects: a. The subject fully understands the requirements of this study and voluntarily signs a written informed consent form; b. Can comply with the medication requirements of this study and all study-related procedures and assessments.
- 3.Tumor types meeting the following conditions:
- Phase Ia:
- Subjects with relapsed or metastatic advanced gynecological tumors and triple-negative breast cancer (TNBC) confirmed by histology or cytology and laboratory-confirmed functional loss mutation of TP53, including but not limited to high-grade serous ovarian cancer (HGSOC), uterine carcinosarcoma (UCS), endometrial cancer (EC) and other gynecological tumors, and TNBC.
- Phase Ib:
- Subjects with relapsed or metastatic advanced gynecological tumors and TNBC confirmed by histology or cytology and laboratory-confirmed functional loss mutation of TP53 and genomic doubling (WGD) characteristics, including but not limited to HGSOC, UCS, EC and other gynecological tumors, and TNBC. Specific requirements for each tumor type are as follows:
Show all 18Show fewer
- High-grade serous ovarian cancer: Platinum-resistant ovarian cancer that has progressed/relapsed after at least one line of platinum-containing chemotherapy, or platinum-sensitive ovarian cancer that has progressed/relapsed after at least two lines of platinum-containing chemotherapy. The definition of "platinum-resistant" is: the interval between the discovery of tumor recurrence and the last chemotherapy of the previous platinum-containing regimen is <6 months, or the tumor progresses during initial treatment or recurrence treatment. The definition of "platinum-sensitive" is: the interval between the discovery of tumor recurrence and the last chemotherapy is ≥6 months. The interval should be calculated from the date of the last platinum drug treatment to the date of disease progression.
- Uterine carcinosarcoma: Progressed/relapsed after at least one line of platinum-containing chemotherapy.
- Endometrial cancer: Progressed/relapsed after at least one line of platinum-containing chemotherapy.
- TNBC: Progressed/relapsed after at least one line of chemotherapy. Note: Subjects receiving adjuvant therapy who have disease progression within less than 6 months after the end of treatment can be considered as having received first-line therapy.
- 4.Expected survival time ≥ 12 weeks. 5.Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1. 6.According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 there is at least 1 measurable lesion. Lesions previously treated with local therapy such as radiotherapy are not considered measurable lesions unless there is definite progression after local therapy.
- 7.Subjects have sufficient vital organ function at screening (requirement: no blood transfusion, no use of hematopoietic stimulators or human albumin preparations within 14 days before screening), specifically defined as follows:
- Blood routine: Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L; Platelet count (PLT) ≥100 × 10⁹/L or greater than the laboratory normal value; Hemoglobin (HGB) ≥90 g/L (9 g/dL).
- Liver function: Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN). For subjects with liver metastasis or confirmed Gilbert syndrome, TBIL ≤ 3 × ULN. For subjects without liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. For subjects with liver metastasis, ALT or AST ≤ 5 × ULN.
- Renal function: Creatinine clearance (CLCr) calculated by the Cockcroft-Gault method (Appendix 3: Creatinine Clearance Calculation Formula) ≥ 60 mL/min.
- Coagulation function: Activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 2 × ULN (indicators of subjects receiving anticoagulant therapy are within the therapeutic range).
- Cardiac function standard: Echocardiogram (ECHO) shows left ventricular ejection fraction greater than 50%.
- 8.Serum pregnancy test of female subjects of childbearing age within 7 days before the first use of the study drug must be negative; eligible subjects with fertility must agree to use reliable contraceptive methods (hormonal or barrier methods or abstinence, etc.) with their partners during the trial and for at least 3 months after the last dose. A subject with fertility is defined as sexually mature and having biological potential fertility.
Who cannot join
- 1.Received chemotherapy within 21 days before the first administration of GH2616 tablets, or received radiotherapy, endocrine therapy, immunotherapy and other anti-tumor drug treatments within 28 days before, and special regulations are made for the following anti-tumor drugs or treatments:
- Nitrosourea or mitomycin C: within 6 weeks before the first use of the study drug;
- Oral fluoropyrimidines, small molecule targeted drugs, and traditional Chinese medicine with anti-tumor indications: within 5 half-lives or 14 days before the first use of the study drug (whichever is shorter);
- Local palliative radiotherapy: within 14 days before the first use of the study drug.
- 2.Received other unmarketed clinical research drugs or treatments within 28 days before the first administration.
- 3.Acute toxicity caused by previous anti-tumor treatment before the first administration has not recovered to ≤ Grade 1 of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or the baseline level specified in the inclusion criteria (except for toxicity such as alopecia and fatigue that the investigator judges to have no safety risk).
Show all 27Show fewer
- 4.Mean corrected QT interval (QTc, using Fridericia's correction formula) > 470 ms in resting 12-lead electrocardiogram (ECG) examination (ECG testing frequency can be increased if there are clinical indications). Various clinically significant arrhythmias, conduction, and resting ECG morphological abnormalities, such as complete left bundle branch block, third-degree heart block, etc. Various factors that may increase the risk of QTc prolongation or arrhythmic events, such as Class III heart failure, refractory hypokalemia, congenital long QT syndrome, and first-degree relatives with long QT syndrome in the family history.
- 5.Have persistent or active infection, including: Active hepatitis B (hepatitis B surface antigen (HbsAg) positive and hepatitis B virus deoxyribonucleic acid (HBV-DNA) > 1000 IU/ml or 2000 cps/ml]; Patients infected with hepatitis C virus (defined as positive HCV antibody and HCV-RNA > upper limit of normal).
- 6.Symptomatic or active progressive central nervous system (CNS) metastasis. 7.Uncontrolled concurrent diseases, such as:
- Severe infection within 14 days before starting study treatment, including but not limited to hospitalization for infection, bacteremia, or severe pneumonia complications; or received therapeutic intravenous antibiotics within two weeks before starting study treatment. Subjects using prophylactic antibiotics for biopsy can be enrolled;
- Heart failure meeting New York Heart Association functional class ≥III within 6 months before starting study treatment;
- Having other malignant tumors within 5 years before starting treatment or at the same time (except for in situ cancers such as non-melanoma skin basal cell carcinoma or squamous cell carcinoma, breast/cervical carcinoma in situ, superficial bladder cancer, etc. that have been radically treated and have no evidence of disease recurrence);
- Subjects with current or previous history of carcinomatous meningitis, spinal cord compression, etc.;
- Uncontrolled hypertension within 7 days before starting study treatment, defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg even under treatment with multiple antihypertensive drugs;
- Any arterial thromboembolic event within 6 months before starting study treatment, including acute myocardial infarction, cerebrovascular accident, or transient ischemic attack;
- Tumor invades surrounding vital organs or blood vessels (such as mediastinal great vessels, superior vena cava, trachea, esophagus, etc.), or there is a risk of developing esophagotracheal fistula or esophagopleural fistula;
- After esophageal or tracheal lumen stent implantation;
- History of gastrointestinal perforation and/or fistula within 6 months before starting study treatment;
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently);
- Uncontrolled tumor-related pain, or no stable pain treatment plan. 8.Allergic to GH2616 tablets or its formulation components. 9.Have significant impact on oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction.
- 10.Subjects have severe underlying lung disease or history, such as severe chronic obstructive pulmonary disease, unhealed interstitial lung disease, unhealed acute or chronic infectious pneumonia, lung transplantation, etc.
- 11.Use of strong inhibitors and strong inducers of P-glycoprotein (P-gp) within 14 days or 5 half-lives before the first administration (whichever is longer).
- 12.Pregnant or lactating women. 13.Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- 14.Underwent major surgical operations (craniotomy, thoracotomy, laparotomy, vascular interventional surgery) within 28 days before the first administration, or have unhealed wounds, ulcers, or fractures. Note: Local surgical treatment for isolated lesions for palliative purposes is acceptable.
- 15.Previous history of definite mental disorder and taking medication for treatment.
- 16.Previous treatment with KIF18A inhibitor. 17.Have POLE hotspot mutation, dMMR/MSI-H, or identifiable hypermutator phenotype.
- 18.The investigator deems that the subject is not suitable to participate in this clinical study for other reasons.
Trial locations and contacts
2 sites in 1 country.
China2 sites
Peking Union Medical College Hospital
Beijing, Beijing Municipality
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality
About this study
GH2616 is a potent and selective inhibitor targeting KIF18A, exhibiting distinct and superior anticancer properties compared to other cell cycle and anti-mitotic drug targets, with significant inhibitory effects on TP53 mutant and WGD (whole genome doubling) or CIN (chromosomal instability) tumors. GH2616 regulates chromosome distribution and alignment, prolongs mitotic duration, and activates the spindle assembly checkpoint by inhibiting KIF18A activity, thereby arresting mitosis at the G2/M phase, inducing mitotic catastrophe, and ultimately achieving tumor suppression.
This study will evaluate the safety and tolerability of GH2616 in patients with advanced solid tumors, and determine its dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D).
- Conditions
- Advanced Solid Tumor Cancer
- Being tested
- GH2616 Tablets for oral administration at specified doses on scheduled days.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GH2616 Tablets for oral administration at specified doses on scheduled days.Drug
Drug: GH2616 Treatment group: Subjects will receive GH2616 orally in a dose escalation until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the study.
| Study group | Role | What they receive |
|---|---|---|
| GH2616 Tablet Group | Experimental | GH2616（Phase 1a：Dose Escalation） Subjects with advanced solid tumors harboring functional loss mutations of TP53 will be enrolled in dose escalation cohorts. Dose escalation of GH2616 will be conducted to determine the maximum tolerated dose (MTD).
GH2616（Phase 1b：Dose Expansion） Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumor harboring functional loss mutations of TP53 and whole genome doubling (WGD) characteristics. Receives: Drug: GH2616 Tablets for oral administration at specified doses on scheduled days. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0).
Evaluated at each dose level GH2616, as graded by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0.
Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment. Approximately 2 years.
Phase Ia: Dose Limited Toxicity (DLT)
Evaluated at each dose level GH2616, as graded by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0.
Measured: 21 Days (first cycle)
Phase Ib: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0).
Evaluated at each dose level GH2616, as graded by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0.
Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment. Approximately 2 years.
Phase Ib:- Objective response rate (ORR)
The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.
Measured: Day 1 through 12 cycles (each cycle is 21 days)
Secondary outcomes (6)
Phase Ia and Phase Ib-- Evaluation of pharmacokinetics: plasma concentrations at different times after dosing and related assessment of conventional pharmacokinetic parameters
Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--Duration of Response (DOR)
Antitumor activity was evaluated by assessing tumor response using RECIST 1.1 criteria.
Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--Disease Control Rate (DCR)
Antitumor activity was evaluated by assessing tumor response using RECIST 1.1 criteria.
Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--Progression-Free Survival (PFS)
Antitumor activity was evaluated by assessing tumor response using RECIST 1.1 criteria.
Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ib--Overall Survival (OS)
Antitumor activity was evaluated by assessing tumor response using RECIST 1.1 criteria.
Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--QT Interval Evaluation.
To assess the relationship between plasma concentrations of GH2616 Tablets and QT interval changes in subjects with advanced solid tumors after oral administration.
Measured: Collection will be conducted until Cycle 13.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2025
- Study start27 Mar 2025
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid Tumor CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 126 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Suzhou Genhouse Bio Co., Ltd.
- Sponsor type
- University, hospital or other
- Collaborators
- GCP ClinPlus Co., Ltd., Jiaxing Yidixi Computer Technology Co., Ltd, Nanjing CR Medicon Technology Co., Ltd., Nanjing Shihejiyin Technology, Inc., Fudan University, Peking Union Medical College Hospital
- Responsible party
- Sponsor
- Investigators
- QIAN DONG, MASTER, Study director, Suzhou Genhouse Bio Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07260513
- Sponsor's protocol ID
- GH2616C102
- Acronym
- GH2616C102
- Status last verified
- Nov 2025
- First submitted
- 21 Nov 2025
- Last updated
- 3 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
- ClinicalTrials.gov ID
- NCT07260513
- Acronym / sponsor ID
- GH2616C102 / GH2616C102
- Conditions
- Advanced Solid Tumor Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 126 participants (estimated)
- Lead sponsor
- Suzhou Genhouse Bio Co., Ltd.University, hospital or other
- Collaborators
- GCP ClinPlus Co., Ltd., Jiaxing Yidixi Computer Technology Co., Ltd, Nanjing CR Medicon Technology Co., Ltd., Nanjing Shihejiyin Technology, Inc., Fudan University, Peking Union Medical College Hospital
- Study start
- 27 Mar 2025 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 3 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
GH2616 is a potent and selective inhibitor targeting KIF18A, exhibiting distinct and superior anticancer properties compared to other cell cycle and anti-mitotic drug targets, with significant inhibitory effects on TP53 mutant and WGD (whole genome doubling) or CIN (chromosomal instability) tumors. GH2616 regulates chromosome distribution and alignment, prolongs mitotic duration, and activates the spindle assembly checkpoint by inhibiting KIF18A activity, thereby arresting mitosis at the G2/M phase, inducing mitotic catastrophe, and ultimately achieving tumor suppression.
This study will evaluate the safety and tolerability of GH2616 in patients with advanced solid tumors, and determine its dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| GH2616 Tablet Group | Experimental | Drug: GH2616 Tablets for oral administration at specified doses on scheduled days.GH2616（Phase 1a：Dose Escalation） Subjects with advanced solid tumors harboring functional loss mutations of TP53 will be enrolled in dose escalation cohorts. Dose escalation of GH2616 will be conducted to determine the maximum tolerated dose (MTD). GH2616（Phase 1b：Dose Expansion） Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumor harboring functional loss mutations of TP53 and whole genome doubling (WGD) characteristics. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- 1.Female, aged ≥18 years. 2.Assessed by the investigator as suitable for participation in this study in the following two aspects: a. The subject fully understands the requirements of this study and voluntarily signs a written informed consent form; b. Can comply with the medication requirements of this study and all study-related procedures and assessments.
- Subjects with relapsed or metastatic advanced gynecological tumors and triple-negative breast cancer (TNBC) confirmed by histology or cytology and laboratory-confirmed functional loss mutation of TP53, including but not limited to high-grade serous ovarian cancer (HGSOC), uterine carcinosarcoma (UCS), endometrial cancer (EC) and other gynecological tumors, and TNBC.
- Subjects with relapsed or metastatic advanced gynecological tumors and TNBC confirmed by histology or cytology and laboratory-confirmed functional loss mutation of TP53 and genomic doubling (WGD) characteristics, including but not limited to HGSOC, UCS, EC and other gynecological tumors, and TNBC. Specific requirements for each tumor type are as follows:
- High-grade serous ovarian cancer: Platinum-resistant ovarian cancer that has progressed/relapsed after at least one line of platinum-containing chemotherapy, or platinum-sensitive ovarian cancer that has progressed/relapsed after at least two lines of platinum-containing chemotherapy. The definition of "platinum-resistant" is: the interval between the discovery of tumor recurrence and the last chemotherapy of the previous platinum-containing regimen is <6 months, or the tumor progresses during initial treatment or recurrence treatment. The definition of "platinum-sensitive" is: the interval between the discovery of tumor recurrence and the last chemotherapy is ≥6 months. The interval should be calculated from the date of the last platinum drug treatment to the date of disease progression.
- Uterine carcinosarcoma: Progressed/relapsed after at least one line of platinum-containing chemotherapy.
Key exclusion criteria (27 listed)
- 1.Received chemotherapy within 21 days before the first administration of GH2616 tablets, or received radiotherapy, endocrine therapy, immunotherapy and other anti-tumor drug treatments within 28 days before, and special regulations are made for the following anti-tumor drugs or treatments:
- 2.Received other unmarketed clinical research drugs or treatments within 28 days before the first administration.
- 3.Acute toxicity caused by previous anti-tumor treatment before the first administration has not recovered to ≤ Grade 1 of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or the baseline level specified in the inclusion criteria (except for toxicity such as alopecia and fatigue that the investigator judges to have no safety risk).
- 4.Mean corrected QT interval (QTc, using Fridericia's correction formula) > 470 ms in resting 12-lead electrocardiogram (ECG) examination (ECG testing frequency can be increased if there are clinical indications). Various clinically significant arrhythmias, conduction, and resting ECG morphological abnormalities, such as complete left bundle branch block, third-degree heart block, etc. Various factors that may increase the risk of QTc prolongation or arrhythmic events, such as Class III heart failure, refractory hypokalemia, congenital long QT syndrome, and first-degree relatives with long QT syndrome in the family history.
- 5.Have persistent or active infection, including: Active hepatitis B (hepatitis B surface antigen (HbsAg) positive and hepatitis B virus deoxyribonucleic acid (HBV-DNA) > 1000 IU/ml or 2000 cps/ml]; Patients infected with hepatitis C virus (defined as positive HCV antibody and HCV-RNA > upper limit of normal).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GH2616 Tablets for oral administration at specified doses on scheduled days.Drug: GH2616 Treatment group: Subjects will receive GH2616 orally in a dose escalation until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the study. | Drug | GH2616 Tablet Group |
Primary outcome
Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0).
Time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment. Approximately 2 years.
Evaluated at each dose level GH2616, as graded by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0.
Phase Ia: Dose Limited Toxicity (DLT)
Time frame: 21 Days (first cycle)
Evaluated at each dose level GH2616, as graded by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0.
Phase Ib: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0).
Time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment. Approximately 2 years.
Evaluated at each dose level GH2616, as graded by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0.
Phase Ib:- Objective response rate (ORR)
Time frame: Day 1 through 12 cycles (each cycle is 21 days)
The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.
6 secondary outcomes
Phase Ia and Phase Ib-- Evaluation of pharmacokinetics: plasma concentrations at different times after dosing and related assessment of conventional pharmacokinetic parameters
Time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--Duration of Response (DOR)
Time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--Disease Control Rate (DCR)
Time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--Progression-Free Survival (PFS)
Time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ib--Overall Survival (OS)
Time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment.
Phase Ia and Phase Ib--QT Interval Evaluation.
Time frame: Collection will be conducted until Cycle 13.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Advanced Solid Tumor Cancer
RecruitingPhase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-small-Cell Lung
RecruitingPhase 1
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Advanced Stage Solid Tumors
RecruitingPhase 1/2
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
Active, not recruitingPhase 1/2
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
Advanced Solid Tumors
RecruitingPhase 1
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Advanced-stage Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
QIAN DONG, MASTER study director
Suzhou Genhouse Bio Co., Ltd.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing GH2616 Tablets for oral administration at specified doses on scheduled days. in people with Advanced Solid Tumor Cancer, run by Suzhou Genhouse Bio Co., Ltd. at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0). (time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment. Approximately 2 years.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.